Fernando Luis Pagan MD

Movement Disorder

Vice Chairman of Neurology Professor of Neurology, Medstar Georgetown University Hospital Director of the Movement Disorders Program Translational Neurotherapeutics Program Georgetown University School of Medicine Medstar Georgetown University Hospital

Join to View Full Profile

1420 Beverly RoadSte 300McLean, VA 22101
Phone+1 202-295-0540
Fax+1 202-444-2661

Education & Training

MedStar Health Georgetown UniversityResidency, Neurology, 1997 - 2000
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1996 - 1997
Georgetown University School of MedicineClass of 1996

Certifications & Licensure

DC State Medical License 1997 - 2026
VA State Medical License 2008 - 2026
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology

Awards, Honors, & Recognition

Alpha Omega Alpha Honor Society AOA, 2016
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Start of enrollment: 2012 Jan 01
Completed
Phase 4
Parkinson's Foundation Quality Improvement Initiative Start of enrollment: 2009 Jul 01
Completed
Myobloc Atrophy Study Start of enrollment: 2014 May 01
Completed
Phase 4
Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood Start of enrollment: 2013 Oct 01
Completed
Phase 1
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease Start of enrollment: 2017 Jan 01
Active, not recruiting
Phase 2
Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Start of enrollment: 2019 Apr 23
Completed
Phase 2
K0706 for Patients Diagnosed With Dementia With Lewy Bodies Start of enrollment: 2019 Sep 05
Recruiting
Phase 2
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies Start of enrollment: 2019 Jul 01
Recruiting
Phase 2
Istradefylline Effect Protocol on Parkinson's Disease Tremor Start of enrollment: 2023 Jan 20
COMPLETED
PHASE4
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease Start of enrollment: 2025 Feb 12
RECRUITING
PHASE4
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients Start of enrollment: 2007 Jul 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib.
Fernando Pagan, Yasar Torres-Yaghi, Michaeline Hebron, Barbara Wilmarth, R Scott Turner
Journal of Clinical Medicine. 2025-06-14
1 citations
Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Yasar Torres-Yaghi, Joyce Qian, Hannah Cummings, Hiroo Shimoda, Satoru Ito
Clinical Neuropharmacology. 2025-01-13
1 citations
Delphi Analysis: Optimizing Anatomy Teaching and Ultrasound Training for Botulinum Neurotoxin Type A Injection in Spasticity and Dystonia.
Kimberly Heckert, Bo Biering-Sørensen, Tobias Bäumer, Omar Khan, Fernando Pagan
Toxins. 2024-08-21

Press Mentions

Cancer Drug Nilotinib Could Treat Parkinson's Disease and Restore Movement in Patients, Finds StudyDecember 25th, 2019
Nilotinib Appears Safe in Parkinson’s Trial; Drug Thought to Allow Dopamine ReplenishmentDecember 17th, 2019
Cancer Drug Shows Promise in Battling Parkinson’s DiseaseDecember 17th, 2019
Join now to see all